Business Description
Theralase Technologies Inc
NAICS : 334510
SIC : 3912
ISIN : CA88337V1004
Description
Financial Strength
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 1.26 | |||||
Equity-to-Asset | 0.49 | |||||
Debt-to-Equity | 0.21 | |||||
Debt-to-EBITDA | -0.08 | |||||
Piotroski F-Score | N/A/9 | |||||
Altman Z-Score | -15.68 | |||||
WACC vs ROIC |
Growth Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 9.9 | |||||
3-Year EPS without NRI Growth Rate | 6.6 | |||||
3-Year FCF Growth Rate | 6.2 | |||||
3-Year Book Growth Rate | -43.8 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 213.32 |
Momentum Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 61.83 | |||||
9-Day RSI | 56.87 | |||||
14-Day RSI | 53.85 | |||||
6-1 Month Momentum % | 12.5 | |||||
12-1 Month Momentum % | -21.74 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.21 | |||||
Quick Ratio | 0.77 | |||||
Cash Ratio | 0.29 | |||||
Days Inventory | 478.14 | |||||
Days Sales Outstanding | 20.19 | |||||
Days Payable | 512.82 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -3.8 | |||||
Shareholder Yield % | -4.15 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 48.92 | |||||
Operating Margin % | -480.59 | |||||
Net Margin % | -478.09 | |||||
FCF Margin % | -365.08 | |||||
ROE % | -246.09 | |||||
ROA % | -136.6 | |||||
ROIC % | -209.88 | |||||
3-Year ROIIC % | 126.35 | |||||
ROC (Joel Greenblatt) % | -531.23 | |||||
ROCE % | -211.29 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 45 | |||||
PB Ratio | 25.71 | |||||
Price-to-Tangible-Book | 25.71 | |||||
EV-to-EBIT | -10.07 | |||||
EV-to-EBITDA | -10.76 | |||||
EV-to-Revenue | 47.84 | |||||
EV-to-Forward-Revenue | 29.39 | |||||
EV-to-FCF | -13.1 | |||||
Price-to-Median-PS-Value | 1.5 | |||||
Earnings Yield (Greenblatt) % | -9.93 | |||||
FCF Yield % | -7.62 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Theralase Technologies Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil C$) | 0.922 | ||
EPS (TTM) (C$) | -0.022 | ||
Beta | 0.82 | ||
Volatility % | 72.89 | ||
14-Day RSI | 53.85 | ||
14-Day ATR (C$) | 0.008343 | ||
20-Day SMA (C$) | 0.172 | ||
12-1 Month Momentum % | -21.74 | ||
52-Week Range (C$) | 0.14 - 0.275 | ||
Shares Outstanding (Mil) | 245.54 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 9999 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Theralase Technologies Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Theralase Technologies Inc Stock Events
Event | Date | Price(C$) | ||
---|---|---|---|---|
No Event Data |
Theralase Technologies Inc Frequently Asked Questions
What is Theralase Technologies Inc(TSXV:TLT)'s stock price today?
When is next earnings date of Theralase Technologies Inc(TSXV:TLT)?
Does Theralase Technologies Inc(TSXV:TLT) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |